Trials / Completed
CompletedNCT03939767
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
Evaluation of an eXtended and proacTive Dosing regimEn in Treatment-Naïve Patients With Wet Age-related Macular Degeneration (wAMD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,563 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, BAY86-5321) | As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study. |
Timeline
- Start date
- 2019-05-12
- Primary completion
- 2023-07-07
- Completion
- 2023-10-17
- First posted
- 2019-05-07
- Last updated
- 2024-09-20
Locations
17 sites across 17 countries: Argentina, Australia, Belgium, Canada, China, Colombia, Denmark, France, Ireland, Italy, Norway, South Korea, Spain, Sweden, Switzerland, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT03939767. Inclusion in this directory is not an endorsement.